*The following content is generated by AI and is for reference only.
<h3>Overview</h3>
<p><strong>(3R,5S,6E)-7-[4-(4-Fluorophenyl)-6-isopropyl-2-[(methanesulfonyl)methylamino]pyrimidin-5-yl]-3,5-dihydroxy-1,4-dioxane-2-carboxylic acid</strong> is a high-purity chiral intermediate for antiviral pharmaceuticals. Synthesized via asymmetric catalytic hydrogenation and precise acylation. CAS: 209264-38-6.</p>
<h3>Application</h3>
<ul>
<li><strong>Viral Inhibition:</strong> Key scaffold for developing novel SARS-CoV-2 main protease inhibitors.</li>
<li><strong>Pharmaceutical R&D:</strong> Used in clinical trial formulations targeting RNA-dependent RNA polymerase.</li>
<li><strong>API Manufacturing:</strong> Essential building block for large-scale production of direct-acting antivirals.</li>
</ul>
<h3>Precautions</h3>
<p>Store under inert atmosphere at -20°C to prevent hydrolysis. Requires N95 respirators and chemical-resistant gloves during handling due to potential mutagenicity. Strictly regulated for human use only; industrial grades require specific export licensing.</p>